Literature DB >> 11545191

Diagnostic usefulness of FDG PET for pancreatic mass lesions.

K Koyama1, T Okamura, J Kawabe, B Nakata, K H Chung, H Ochi, R Yamada.   

Abstract

UNLABELLED: The purpose of this study was to investigate the feasibility of [18F]2-deoxy-2-fluoro-D-glucose (FDG) positron emission tomography (PET) in patients with a pancreatic mass by comparing the results with those of X-ray computed tomography (CT) and magnetic resonance (MR) imaging.
METHODS: Eighty-six patients with pancreatic lesions, included 65 malignant tumors and 21 benign masses (55 masses were proven histologically and the others were diagnosed clinically), were studied. The diagnostic factors of CT and MR imaging were evaluated, and those of FDG PET were also evaluated for malignant and benign masses by visual interpretation and quantitative interpretation with the standardized uptake value (SUV) and SUVgluc which was designed to reduce the effects of a high blood sugar level. Visual interpretations were evaluated only in FDG PET images, and quantitative interpretations were evaluated by referring to CT and/or MR imaging. The correlation between SUV and the degree of histological differentiation in pancreatic ductal adenocarcinoma was investigated.
RESULTS: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for CT imaging were 91, 62, 88, 68 and 84%, and for MR imaging 78, 70, 88, 54 and 76%, respectively. In visual interpretation of FDG PET images, the sensitivity, specificity, PPV, NPV and accuracy were 82, 81, 93, 59 and 81%, respectively. Significant differences between malignant and benign lesions existed in SUV and SUVgluc (p < 0.0001, each). With the cutoff value of SUV as 2.1 and SUVgluc as 2.2, the accuracy of diagnosis was maximal. With that cutoff value, the sensitivity, specificity, PPV, NPV and accuracy for SUV were 89, 76, 92, 70 and 86%, and for SUVgluc 91, 76, 92, 73 and 87%, respectively. The sensitivity and NPV of SUVgluc were higher than those of SUV, which suggests that SUVgluc may be more useful in reducing the number of overlooked malignant tumors. The specificity and PPV of FDG PET were superior to those of CT and MR imaging. There were no significant differences between the SUVs of moderately differentiated adenocarcinomas and those of well differentiated adenocarcinomas.
CONCLUSION: To improve the diagnostic procedure for classifying masses, FDG PET with not only SUV but also SUV corrected by the blood sugar level is required in addition to morphological diagnosis by CT and/or MR imaging.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11545191     DOI: 10.1007/bf02987835

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  18 in total

1.  Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection.

Authors:  Kojun Okamoto; Isamu Koyama; Mitsuo Miyazawa; Yasuko Toshimitsu; Masayasu Aikawa; Katsuya Okada; Etsuko Imabayashi; Hiroshi Matsuda
Journal:  Int J Clin Oncol       Date:  2010-09-23       Impact factor: 3.402

2.  FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis.

Authors:  Zhen Wang; Jun-Qiang Chen; Jin-Lu Liu; Xin-Gan Qin; Yuan Huang
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

3.  Pilot study: Evaluation of dual-energy computed tomography measurement strategies for positron emission tomography correlation in pancreatic adenocarcinoma.

Authors:  Jorge Oldan; Miao He; Teresa Wu; Alvin C Silva; Jing Li; J Ross Mitchell; William M Pavlicek; Michael C Roarke; Amy K Hara
Journal:  J Digit Imaging       Date:  2014-12       Impact factor: 4.056

4.  Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements.

Authors:  Mahsa Eskian; Abass Alavi; MirHojjat Khorasanizadeh; Benjamin L Viglianti; Hans Jacobsson; Tara D Barwick; Alipasha Meysamie; Sun K Yi; Shingo Iwano; Bohdan Bybel; Federico Caobelli; Filippo Lococo; Joaquim Gea; Antonio Sancho-Muñoz; Jukka Schildt; Ebru Tatcı; Constantin Lapa; Georgia Keramida; Michael Peters; Raef R Boktor; Joemon John; Alexander G Pitman; Tomasz Mazurek; Nima Rezaei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-22       Impact factor: 9.236

5.  Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.

Authors:  Jacob L Houghton; Brian M Zeglis; Dalya Abdel-Atti; Ritsuko Sawada; Wolfgang W Scholz; Jason S Lewis
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

6.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

7.  The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions.

Authors:  Masatoyo Nakajo; Seishi Jinnouchi; Yoshihiko Fukukura; Hiroaki Tanabe; Rie Tateno; Masayuki Nakajo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-23       Impact factor: 9.236

8.  18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Kyohei Ariake; Fuyuhiko Motoi; Hideo Shimomura; Masamichi Mizuma; Shimpei Maeda; Chiaki Terao; Yasuko Tatewaki; Hideo Ohtsuka; Koji Fukase; Kunihiro Masuda; Hiroki Hayashi; Tatsuyuki Takadate; Takeshi Naitoh; Yasuyuki Taki; Michiaki Unno
Journal:  J Gastrointest Surg       Date:  2017-11-08       Impact factor: 3.452

Review 9.  [PET and PET-CT of malignant tumors of the exocrine pancreas].

Authors:  S N Reske
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

10.  Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.

Authors:  Hisao Wakabayashi; Yoshihiro Nishiyama; Tsuyoshi Otani; Takanori Sano; Shinichi Yachida; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.